Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evaxion Biotech ( (EVAX) ) has shared an announcement.
Evaxion A/S has called its 2026 annual general meeting for April 16, 2026, in Hørsholm, Denmark, with shareholders set to review the 2025 audited annual report, receive a board update on the past year’s activities, and decide that the 2025 loss be carried forward. The agenda also includes re-election of the current directors, the proposed election of Jens Bitsch-Nørhave to the board, reappointment of EY as auditor, and new authorizations to expand warrant issuances and raise financing via convertible loans without pre-emptive rights, moves that would increase the company’s flexibility to incentivize management and access future equity-linked funding.
Shareholders will further be asked to authorize the meeting chairman to handle any technical amendments needed for registration of the resolutions with the Danish Business Authority. These governance and capital-authorization proposals, if approved, would strengthen Evaxion’s ability to manage its capital structure and support ongoing operations amid continued losses while maintaining alignment with Danish corporate law and U.S. listing requirements.
The most recent analyst rating on (EVAX) stock is a Sell with a $3.50 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
The score is driven primarily by improved capitalization but still-weak cash generation and profitability. Technicals are moderately favorable with improving momentum, while valuation remains limited by losses. Earnings-call commentary adds support via clear milestone roadmap, strong EVX-01 results, and runway into H2 2027, tempered by dilution/partnering execution risks.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S is a Danish biotech company based in Hørsholm that develops its business under the regulatory framework of the U.S. Securities and Exchange Commission as a foreign private issuer. The company is listed in the United States and operates with a board and governance structure that includes independent directors and external auditors, reflecting its capital markets focus.
Average Trading Volume: 57,426
Technical Sentiment Signal: Sell
Current Market Cap: $31.53M
Learn more about EVAX stock on TipRanks’ Stock Analysis page.